More on AstraZeneca (AZN +1.5%) Q2: Earnings after taxation -24% to $1.61B, hurt by generic...


More on AstraZeneca (AZN +1.5%) Q2: Earnings after taxation -24% to $1.61B, hurt by generic competition to its Seroquel antipsychotic medicine, reduced health spending in Europe, and supply chain difficulties due to IT problems. Reiterates FY forecast for core EPS of $5.85-$6.15 vs. consensus of $5.83, and $7.28 in 2011, and for sales to fall by a low- to mid-teen percentage vs. consensus of -14.9% to $28.6B.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs